Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,001–11,100 of 15,747
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.11.14.22282103 · Cited by 3
Attitudes and Beliefs of the Italian Population towards COVID-19 Vaccinations
Rania, N., Coppola, I., Brucci, M., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19106139 · Cited by 3
“However a lot of research finds COVID-19 vaccination to be safe with only minor adverse effects [18,19] even among patients with particular diseases [20], pregnant women [21] and children [22].”
BackgroundmRNA and Peptide Vaccines in Melanoma—Current Landscape and Future Direction
Qin, J. J., Wang, Y., & Sandhu, S. (2026) · Cells · doi:10.3390/cells15040344 · Cited by 5
Sahoo, S. S., Kaur, N., Kaur, A., et al. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221124018 · Cited by 3
Imidazolium lipid-based nanoparticles enable effective mRNA delivery and cellular immune response
Lin, J., Zhu, Y., Cheng, L., Wei, C. Y., Kong, J., Choy, J., Lu, X., Yu, D., Ma, J., Liu, X., et al. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103265 · Cited by 3
Kurihara, C., & Saio, T. (2023) · Springer eBooks · doi:10.1007/978-981-99-6163-4_6 · Cited by 3
Wang, G., Zhao, K., Zhao, X., Cui, Y., He, P., Zhang, T., Wang, Y., Shi, R., Li, Y., Wang, Q., et al. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2456231 · Cited by 3
Turabián, J. L. (2022) · Journal of SARS-CoV-2 Research · doi:10.36013/sarc-cov-2.v2i.85 · Cited by 4
Bando, H., Yamamoto, M., Takahashi, M., Kanie, K., Sasaki, Y., Oi, Y., Tomofuji, S., Hozumi, K., Nishikage, S., Urai, S., et al. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0390 · Cited by 3
Comparison of Adverse Effects of COVID-19 Vaccines Among Elderly: Pfizer/BioNTech Versus CoronaVac
Evren, H., Evren, E. Ü., Barış, S. A., İNCE, F. G., SOYDAN, C., Elci, Ö. C., & Yıldız, F. (2023) · Acibadem Universitesi Saglik Bilimleri Dergisi · doi:10.31067/acusaglik.1076933 · Cited by 3
“Data about the side effects of vaccination in specific groups such as the elderly and those with comorbidities remains lacking (4-6).”
BackgroundSARS-CoV-2 infection after vaccination in Italian health care workers: a case report
Cafiero, C., Palmirotta, R., Micera, A., Ottaiano, M. P., Re, A., Pedata, F., Costagliola, D., Ponticelli, D., Pisconti, S., Schiavone, B., et al. (2022) · National Academy Science Letters · doi:10.1007/s40009-022-01106-w · Cited by 4
Single-Dose Ad26.COV2.S Vaccine—Room for Improvement
Tehrani, Z. R., & Sajadi, M. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.33012 · Cited by 3
Khidir, K. A. (2021) · PubMed Central · doi:10.22092/ari.2021.355737.1714 · Cited by 4
“pharmaceutical companies have shown 90%-95% effectiveness (3, 4).”
BackgroundAso, S., Ono, S., Michihata, N., Uemura, K., & Yasunaga, H. (2024) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2024.272 · Cited by 4
Cross-Sectional Survey of Views on COVID-19 and Its Vaccines Among Pregnant Women
Li, Y. Y., Lok, W., Poon, L. C., Kong, C. W., & To, W. W. K. (2022) · Maternal-Fetal Medicine · doi:10.1097/fm9.0000000000000149 · Cited by 3
Magoola, M., & Niazi, S. K. (2025) · Vaccines · doi:10.3390/vaccines13090970 · Cited by 11
“• Consensus and Chimeric Sequences Consensus antigens incorporating epitopes from multiple pathogen strains reduce the likelihood of complete neutralization by any individual’s pre-existing immunity [49].”
COVID-19 Vaccine Intention among Rural Residents in Mexico: Validation of a Questionnaire
Álvarez-Manzo, H. S., Badillo-Davila, R., Olaya-Gomez, A., González-de-Cossío-Tello, B., Cardoso-Arias, R., Gamboa-Balzaretti, E. S., Baranzini-Rogel, C. D., García-Garnica, G., Hernandez-Corrales, L. E., & Linares-Koloffon, C. A. (2021) · Vaccines · doi:10.3390/vaccines9090952 · Cited by 8
“In December 2020, after demonstrating 95% effectiveness against COVID-19 infection [6], the United States Food and Drug Administration approved the emergency use of the COVID-19 vaccine produced by Pfizer-BioNTech [7].”
BackgroundBragazzi, N. L., Buchinger, M., Szarpak, Ł., Chmielewski, J. P., Goździewska, M., Gotlib, J., & Khamisy‐Farah, R. (2023) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/176959 · Cited by 3
Effectiveness of England’s initial vaccine roll out
Lisewski, A. M. (2021) · BMJ · doi:10.1136/bmj.n1201 · Cited by 4
COVID-19 and the Unraveling of Experimental Medicine - Part II
Thorp, K. E., & Thorp, J. A. (2022) · The Gazette of Medical Sciences · doi:10.46766/thegms.pubheal.22022804 · Cited by 6
Chen, Y., Song, Y., Zhu, X., Dong, C., & Chen, M.-S. (2023) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2023.2281462 · Cited by 3
Tschiderer, L., Innerhofer, H., Seekircher, L., Waltle, L., Richter, L., Kimpel, J., Lass‐Flörl, C., Forer, L., Schönherr, S., Larsen, D. A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111117 · Cited by 3
Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins
Kumar, S., Dasgupta, S., Sajadi, M. M., Snyder, G. A., DeVico, A. L., & Ray, K. (2024) · Viruses · doi:10.3390/v16030407 · Cited by 4
Cantrelle, F., Boll, E., Brier, L., Moschidi, D., Belouzard, S., Landry, V., Leroux, F., Dewitte, F., Landrieu, I., Dubuisson, J., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202109965 · Cited by 3
O’Regan, E., Svalgaard, I. B., Sørensen, A. I. V., Spiliopoulos, L., Bager, P., Nielsen, N. M., Hansen, J. V., Koch, A., Meder, I. K., Videbech, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00844-w · Cited by 3
Cremer, L., Bethe, U., Borchmann, P., Cristanziano, V. D., Gieselmann, L., Grimm, S., Hellmich, M., Jakobs, J., Nacov, J. A., Neuhann, J., et al. (2025) · JMIR Research Protocols · doi:10.2196/60675 · Cited by 3
Κοντοπούλου, Κ., Nakas, C. T., Ainatzoglou, A., Gkounti, G., Katsioulis, C., & Papazisis, G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3922311 · Cited by 3
Davda, J. P., Reynolds, K. S., Davis, J. D., & Smith, P. F. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14859 · Cited by 3
Proactive COVID-19 testing in a partially vaccinated populationPreprint
McGee, R. S., Homburger, J. R., Williams, H., Bergstrom, C. T., & Zhou, A. Y. (2021) · medRxiv · doi:10.1101/2021.08.15.21262095 · Cited by 4
Management of vaccinations in patients with non‐Hodgkin lymphoma
Merli, M., Costantini, A., Tafuri, S., Bavaro, D. F., Minoia, C., Meli, E., Luminari, S., & Gini, G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19422 · Cited by 7
“34 A seminal Israeli study evaluating 149 patients with either aggressive or indolent NHL showed that overall serological responses to the BNT162b2 vaccine were nearly halved compared to the healthy controls (49% vs. 98.5%, p 0.001).”
BackgroundInfluentialFunakoshi, Y., Yakushijin, K., Ohji, G., Matsutani, T., Doi, K., Sakai, H., Sasaki, T., Kusakabe, T., Matsumoto, S., Saito, Y., et al. (2024) · eJHaem · doi:10.1002/jha2.932 · Cited by 4
“ThesemRNAvaccineswerehighlyeffec-tiveinpreventingsymptomaticCoronavirusDisease2019(COVID-19) in the early phase of the pandemic [1–3].”
BackgroundMielke, N., Johnson, S., O’Sullivan, C., Toseef, M. U., & Bahl, A. (2024) · Journal of Clinical Medicine Research · doi:10.14740/jocmr5145 · Cited by 3
The COVID-19 Vaccines: A Description of Adverse Events or Reactions Reported in Kansas
Mills, K., Tri, A., & Nilsen, K. M. (2022) · Kansas Journal of Medicine · doi:10.17161/kjm.vol15.15825 · Cited by 3
Cellular and Molecular Mechanisms of SARS-CoV-2 Spike Protein-Induced Endothelial Dysfunction
Muir, K. C., Harris, D. D., Kanuparthy, M., Hu, J. C., Nho, J.-W., Stone, C., Banerjee, D., Sellke, F. W., & Feng, J. (2026) · Cells · doi:10.3390/cells15030234 · Cited by 7
“Large clinical studies have not shown a link between vaccination and generalized endothelial dysfunction, and rare vascular adverse events appear immune-mediated and far less frequent than vascular complications seen with SARS-CoV-2 infection [98,99].”
Secondary Stabbing Headache Associated with COVID-19: a Case Report
Akhlaq, H., Li, M., & Nava, V. E. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01194-1 · Cited by 3
“Vol.:(0123456789) Keywords Unilateral ice-pick cephalagia · SARS-CoA-2 · Vaccine sequela · Case report”
BackgroundInfluentialOne-Year Report of COVID-19 Impact on Geriatric Patients: a Bio-Psycho-Social Approach
Chang, A. Y., & Babb, K. N. (2022) · Canadian Geriatrics Journal · doi:10.5770/cgj.25.553 · Cited by 7
“(61) However, unanticipated effectiveness has been observed, especially in the new generation of mRNA vaccines, which does not appear to be limited by the aging biology.(62) In contrast to annual influenza vaccines which do not confer long-term memory and poorly stimulate T cell response, COVID-19 vaccines based on mR…”
BackgroundKimoto, T., Sakai, S., Kameda, K., Morita, R., Takahashi, E., Shinohara, Y., & Kido, H. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13119 · Cited by 4
Kontandreopoulou, C., Solomou, E. E., Kolorizos, E., & Diamantopoulos, P. T. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05869-8 · Cited by 4
“The primary objective of COVID-19 vaccination was to provide highly effective protection against symptomatic COVID-19 infection, through a combined humoral and cell-mediated immune response while minimizing serious adverse effects [18–20].”
Priority of Vaccination of the Population against COVID-19: Moral Principles
Rashi, T. (2023) · Vaccines · doi:10.3390/vaccines11020380 · Cited by 4
“The UKs healthcare regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), approved the world’s first COVID-19 vaccine for emergency use in December 2020.”
BackgroundInfluentialRojkovich, B., Németh, D., Török, E., Szabó, B., Pintér, Á., Juhász, I., Weidl, M., Lányi, É., Pável-Szecskó, J., Lázár, I., et al. (2021) · Orvosi Hetilap · doi:10.1556/650.2021.32363 · Cited by 3
“A védőoltások [3] bevezetésétől reméljük a pandémia feltartóztatását, a súlyos betegségkimenetel megelőzését.”
BackgroundInmunización para la COVID-19. Diferencias en la tecnología de producción, eficacia y seguridad
Marco, J. J. G., Martínez, A. M., & Bermejo, L. F. (2021) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2021.06.001 · Cited by 3
Seguridad y eficacia preliminar de las vacunas para la prevención de COVID-19
Ciapponi, A. (2021) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v24i1.6912 · Cited by 5
COVID-19 Vaccination Policy: Quo Vadis Fulfillment of Citizen’s Right to Life
Fairuzzaman, F., Rakasiwi, D. A., Wibowo, G. A., & Ayuningtyas, I. R. (2022) · Law and Justice · doi:10.23917/laj.v6i2.15269 · Cited by 5
An Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination
Chowdhury, P., Bhattacharya, S., Gogoi, B., Veeranna, R. P., & Kumar, S. (2022) · Vaccines · doi:10.3390/vaccines10101639 · Cited by 3
Luxi, N., Bellitto, C., Ciccimarra, F., Cappello, E., L’Abbate, L., Bonaso, M., Ajolfi, C., Baldo, P., Bonaiuti, R., Costantino, C., et al. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2024.1363086 · Cited by 3
Bes-Berlandier, H., Coiffard, B., Bermudez, J., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09269-1 · Cited by 3
“The vaccination was considered complete if it included at least 3 doses [17].”
BackgroundNocebo-Prone Behavior Contributes to SARS-CoV-2 Vaccine Hesitancy in Healthcare WorkersPreprint
Mitsikostas, D. D., Aravantinou-Fatorou, K., Deligianni, C. I., KravvaritiM, E., Korompoki, E., Mylona, M., Vryttia, P., Papagiannopoulou, G., Delicha, E.-M., Dellis, A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3923449 · Cited by 3
Wiktorin, H. G., Einarsdottir, S., Törnell, A., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280813 · Cited by 3
Yin, F., Crooks, A. T., & Yin, L. (2024) · International Journal of Geographical Information Systems · doi:10.1080/13658816.2024.2333930 · Cited by 8
“During a global pandemic such as Covid-19, vaccines provide an effective way to protect people against disease and have the potential to save lives (Polack et al. 2020).”
BackgroundChansaenroj, J., Yorsaeng, R., Wanlapakorn, N., Chirathaworn, C., Sudhinaraset, N., Sripram, M., Chalongviriyalert, P., Jirajariyavej, S., Kiatpanabhikul, P., Saiyarin, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1073046/v1 · Cited by 3
Winner, H., Kimpel, J., Krammer, F., von Laer, D., & Paetzold, J. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.39.2101027 · Cited by 3
“…(second sum) the vaccination campaign. β k depicts the difference in outcomes (e.g. incidence among children younger than 16 years) between Schwaz and the border municipalities in any given week relative to the week when the first dose of the vaccination campaign was given (calendar week 10) [17].”
Myocarditis in children 2024, new themes and continued questions
Goldberg, J. F., Spinner, J. A., & Soslow, J. H. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001151 · Cited by 6
Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial
Williams, L. R., Emary, K. R. W., Phillips, D. J., Hay, J., Larwood, J. P. J., Ramasamy, M., Pollard, A. J., Grassly, N. C., & Voysey, M. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126167 · Cited by 5
The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer
Gaur, A., & Chirmule, N. B. (2023) · Springer eBooks · doi:10.1007/978-981-99-2196-6_62-1 · Cited by 4
Leung, J., Primbetova, A., Strong, C., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.09.008 · Cited by 3
COVID-19 Vaccination Outcomes at a Pediatric Long-Term Care Facility
Bickel, S. G., Harris, C. A., Huxol, H., et al. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003185 · Cited by 3
Host-Pathogen Interaction: Biology and Public Health
Ponce‐Cusi, R., Bravo, L., Paez, K. J., Pinto, J. A., & Pilco-Ferreto, N. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3617-6_1 · Cited by 6
Guidelines for Infection and Burnout Prevention in COVID-19 Healthcare Workers
Park, S. Y., Cheong, H. S., Kwon, K. T., Sohn, K. M., Heo, S. T., Lee, S., Chung, U., & Lee, S. H. (2023) · Korean Journal of Healthcare-Associated Infection Control and Prevention · doi:10.14192/kjicp.2023.28.1.50 · Cited by 3
Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19
Almeida, G. G., Pinto, J. A., Pinto, P. M., da Silva, L. B., Andrade, L. A. F., Valiate, B. V. S., Zini, N., Bagno, F. F., Rivelli, G. G., Lourenço, K. L., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127756 · Cited by 4
Kim, Y., Kim, B. I., & Tak, S. (2022) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2022.0212 · Cited by 3
Haraguchi, M., Yamamoto, H., Watanabe, O., Sakoh, T., Ishida, K., Ogura, S., Morishima, M., Taya, Y., Nishida, A., Kaji, D., et al. (2023) · Bone Marrow Transplantation · doi:10.1038/s41409-023-02019-y · Cited by 4
“Vaccination is a reasonable approach to preventing COVID-19 and reducing the risk of severe disease in immunocompetent people [3].”
BackgroundThe Trade-off Between Prioritization and Vaccination Speed Depends on Mitigation MeasuresPreprint
Agarwal, N., Komo, A., Patel, C., Pathak, P., & Unver, U. (2021) · medRxiv · doi:10.1101/2021.02.24.21252352 · Cited by 5
Kayukawa, S., Nanya, K., Morita, M., Ina, K., Ota, Y., & Hasegawa, S. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01036-21 · Cited by 5
“8%) regimen against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was authorized in December 2020 (1).”
BackgroundCOVID ‐19 infection and vaccination in patients with skeletal muscle channelopathies
Vivekanandam, V., Jayaseelan, D. L., & Hanna, M. G. (2022) · Muscle & Nerve · doi:10.1002/mus.27704 · Cited by 3
“Myotonia---MC, SCM, and PMC (24) 10 3 3 24 10 Mexiletine (15); flecainide (10); acetazolamide (2); magnesium (1)”
Yıldırım, S., Erkoyun, E., Alpdoğan, Ö., Yılmaz, H. O., Yılmaz, B., Dönmez, G. E., Sarıtaş, A., Gökmen, A. N., Ergan, B., Bayrak, V., et al. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.06.012 · Cited by 4
“Both vaccines were highly effective against SARS-CoV-2 with good safety and tolerability in phase 3 trials [4,5].”
Nordhorn, I., Weiss, D., Werfel, T., Zink, A., Schielein, M. C., & Traidl, S. (2022) · European Journal of Dermatology · doi:10.1684/ejd.2022.4222 · Cited by 4
“Even though vaccines against SARS-CoV-2 are now available, the consequences of the coronavirus pandemic may continue long after the pandemic resolves [49, 50].”
BackgroundA Cell-Free Assay for Rapid Screening of Inhibitors of hACE2-Receptor–SARS-CoV-2-Spike Binding
Kikuchi, N., Willinger, O., Granik, N., Gal, R., Navon, N., Ackerman, S., Samuel, E., Antman, T., Katz, N., Goldberg, S., et al. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00381 · Cited by 3
COVID-19 Vaccine Effectiveness in a Diverse Urban Health Care Worker Population
Iliaki, E. F., Lan, F., Christophi, C. A., Guidotti, G., Jobrack, A. D., Buley, J., Nathan, N., Osgood, R. A., Bruno‐Murtha, L. A., & Kales, S. N. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.10.005 · Cited by 3
Chan, W. Y., Zhu, C., Sanchez, E., Gupta, R., Fielding, A. K., Khwaja, A., Payne, E. M., & O’Nions, J. (2022) · British Journal of Haematology · doi:10.1111/bjh.18248 · Cited by 3
Neurological Considerations with COVID-19 Vaccinations
Boruah, A. P., Heydari, K., Wapniarski, A. E., Caldwell, M., & Thakur, K. T. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1767725 · Cited by 2
Timing of Bariatric Surgery and COVID-19 Vaccination: Experience From a High-volume Single Center
Vitiello, A., Berardi, G., Velotti, N., Schiavone, V., Abu-Abeid, A., & Musella, M. (2023) · Surgical Laparoscopy Endoscopy & Percutaneous Techniques · doi:10.1097/sle.0000000000001154 · Cited by 2
Song, R., Yang, C., Wang, J., Li, Q., Chen, J., Sun, K., Lv, H., Yang, Y., Liang, J., Ye, Q., et al. (2022) · medRxiv · doi:10.1101/2022.11.12.22282242 · Cited by 3
Krótki, F., Jońca, M., Mariankowska, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1135760/v1 · Cited by 2
Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines
Sohn, W. Y., Goody, S. M. G., Reid, D. W., Edwards, D. K., Urdaneta, V., Doyle, B. P., Straus, W. L., Henry, C., & Rizkalla, B. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128394 · Cited by 4
Diotallevi, F., Simonetti, O., Radi, G., Molinelli, E., Rizzetto, G., Cirioni, O., D’Errico, M. M., & Offidani, A. (2021) · Acta Dermatovenerologica Alpina Pannonica et Adriatica · doi:10.15570/actaapa.2021.16 · Cited by 2
“According to data published by the two companies, the two vaccines seem to have an efficacy of about 95% (7, 8).”
BackgroundSerological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
Rodilla, A. M., Tavolacci, S. C., Cagan, J., Shah, T., Mittan, S., Mack, P. C., & Hirsch, F. R. (2023) · Vaccines · doi:10.3390/vaccines11050969 · Cited by 2
Reactive arthritis (ReA) following the first dose of Covid-19 vaccine; A case report.
Draz, H. E., & Khalifa, A. A. (2022) · Rheumatology (Bulgaria) · doi:10.35465/30.1.2022.pp95-98 · Cited by 2
Allosteric pathways of SARS and SARS‐CoV ‐2 spike protein identified by neural relational inference
Hu, Y., Li, M., & Wang, Q. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26678 · Cited by 3
Mapping the footprints of COVID-19 pandemic
Rastogi, A., Padhi, A., Syed, S., Keshan, P., & Gupta, E. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2361_20 · Cited by 2
“Thus, there is a need to reemphasizing hand hygiene and respiratory etiquettes and continuing the practice of preventive measures even after the Table 2: Description of approved COVID‑19 Vaccine[80] Name Mechanism Doses Efficacy Storage Status Pfizer‑BioNTech: Comirnaty (also known as tozinameran or BNT162b2)[81] mRNA…”
BackgroundQashqari, F. S., Alfelali, M., Barasheed, O., Almaimani, R., Alghamdi, A., Alharbi, S. S., Balahmar, E., Alhothali, A. S., Alsharif, R. H., Jalal, N. A., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s409200 · Cited by 3
“Research shows younger people experience more side effects.(27,33) Alhazmi et al study show that 60% of respondents experienced adverse effects from COVID-19 vaccines, including weariness and soreness.”
BackgroundDíaz-Dinamarca, D. A., Cárdenas-Cáceres, S., Muena, N. A., Díaz, P., Barra, G. N., Puentes, R., Escobar, D. F., Díaz-Samirin, M., Santis-Alay, N. T., Canales, C., et al. (2024) · Vaccines · doi:10.3390/vaccines12080919 · Cited by 1
“The spike can trigger a series of adaptive immune responses mediated by three major cell types: B cells (humoral immunity) and CD4+ and CD8+ T cells (cell-mediated immunity) [12,13].”
BackgroundYoshimoto, N., YANAGI, A., Takayama, S., et al. (2022) · In Vivo · doi:10.21873/invivo.12834 · Cited by 2
Deng, W., Niu, X., He, P., Yan, Q., Liang, H., Wang, Y., Ning, L., Lin, Z., Zhang, Y., Zhao, X., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471396 · Cited by 3
Fredericq, L., Hamouda, A. E. I., Zhong, Z., Ginderachter, J. A. V., Geest, B. G. D., & Laoui, D. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114799 · Cited by 5
Salako, A. O., Musa, A. Z., Ige, F. A., Abdullahi, A., James, A. B., Ekama, S., Odubela, O., Idigbe, I. E., Ajibaye, O., Altaf, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-06536-2 · Cited by 5
Heshin‐Bekenstein, M., Ziv, A., Toplak, N., Hagin, D., Kadishevich, D., Butbul, Y., Saiag, E., Sheffer, G., Sharon, O., Pel, S., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2022-eular.4691 · Cited by 2
Wanchaijiraboon, P., Teeyapun, N., Pakvisal, N., Sainamthip, P., Susiriwatananont, T., Zungsontiporn, N., Suntronwong, N., Vichaiwattana, P., Klinsawat, W., Wanlapakorn, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10101662 · Cited by 2
“Although chemotherapy was a well-known factor associated with a lower level of mRNA vaccine-induced immune response [18], patients receiving chemotherapy were not associated with diminished immune responses in the multivariate analysis.”
BackgroundLi, Y., Samreen, S., Zada, L., Ismail, E. A. A., Awwad, F. A. A., & Hassan, A. M. (2023) · Mathematics · doi:10.3390/math11204253 · Cited by 2
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.28.530547 · Cited by 2
Wang, C., Zhang, X., Li, Q., Hou, Y., Sun, M., Sun, J. Y., Lou, Z., Xu, H., & Li, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138195 · Cited by 6
Bowen, A. D., Zucker, J. E., Shen, Y., Huang, S., Yan, Q., Annavajhala, M. K., Uhlemann, A., Kuhn, L., Sobieszczyk, M. E., & Castor, D. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac436 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.